The present invention provides a diagnostic method for stroke/asymptomatic cerebral infarction and a screening method for patients with stroke/asymptomatic cerebral infarction, which comprise measuring acrolein content or polyamine content; or polyamine oxidase activity or protein content of polyamine oxidase in plasma. The knowledge of the present invention indicates the possibility of preventing, inhibiting the progression of stroke/asymptomatic cerebral infarction by inhibiting polyamine oxidase, and the possibility of obtaining a therapeutic agent for stroke/asymptomatic cerebral infarction by searching for compounds that inhibit polyamine oxidase.

Igarashi; Kazuei

Ueda; Shiro

Saeki; Naokatsu

Kashiwagi; Keiko

Tomitori; Hideyuki

Method of diagnosing apoplectic stroke/asymptomatic brain infarction using acrolein content

The invention generally relates to compounds of formula (I) with neural protective effect, and preparation and uses thereof. ##STR00001## The compounds have multiple mechanisms or functions, for example, inhibition of monoamine oxidase and cholinesterase, scavenging of free radicals, and protection of cells such as nerve cells. The compounds can be used for manufacture of medicaments of cell protection, for prevention and/or treatment of monoamine oxidase, cholinesterase and free radicals related diseases, for example, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and stroke, and free-radical related diseases such as heart disease, myocardial ischemia, diabetes and other cardiovascular and cerebrovascular diseases.

GUANGZHOU MAGPIE PHARMACEUTICAL CO., LTD.

Compounds with neural protective effect, and preparation and use thereof

The combination of 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline or a pharmaceutically acceptable salt thereof with a second therapeutic agent, wherein the second therapeutic agent is selected from: (a) a therapeutic agent known to modify cholinergic transmission such as M1 muscarinic receptor agonists or allosteric modulators, M2 muscarinic antagonists, acetylcholinesterase inhibitors, nicotinic receptor agonists or allosteric modulators, 5-HT4 receptor partial agonists or 5HT1A receptor antagonists and NMDA receptor antagonists or modulators, glutamate antagonists, GABA-ergic antagonists, H3 antagonists, putative metabolic/mitochondrial modulators, or disease modifying agents such as .beta. or .gamma.-secretase inhibitors, Tau-targeted therapeutics, .beta.-amyloid aggregation inhibitors and .beta.-amyloid immunotherapies; (b) an antidepressant such as a tricyclic, a MAOI (Monoamine oxidase inhibitor) a SSRI (Selective Serotonin Reuptake Inhibitor), a SNRI (Serotonin and Noradrenaline Reuptake Inhibitor) or a NaSSA (noradrenergeric and specific serotonergic antidepressant); (c) an atypical antipsychotic, for example olanzapine, clozapine, prisperidone, quentiapine, aripriprazole or paliperiden; or (d) a therapeutic agent suitable for use in Attention Deficit Disorders/Hyperactivity Syndrome, e.g. methylphenidate (Ritalin) or dexamfetamine (Dexedrine), and also the use of 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline or a pharmaceutically acceptable salt thereof for the treatment of: a) psychiatric disorders with prominent cognitive deficits e.g. chronic PTSD (Post traumatic stress disorder); b) non-degenerative disorders with prominent cognitive deficits e.g. MS (multiple Sclerosis), post-chemotherapy, post-CABG (Coronary artery bypass graft), post-stroke; and/or c) paediatric disorders e.g. autism, mental retardation and learning disabilities.

oxidase/moždani udar

Method of diagnosing apoplectic stroke/asymptomatic brain infarction using acrolein content

Compounds with neural protective effect, and preparation and use thereof

Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline

Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline

Najkompletnija baza ljekovitog bilja potpomognuta znanošću